IMDEV acquired by CAPZA
Context
The transaction involves a primary Owner Buy-Out (OBO) where Capza and Bpifrance acquire a minority stake in Imdev to support its next phase of pan-European scaling. This capital injection includes a significant capital increase and a cash-out component for historical shareholders. The strategic rationale is centered on accelerating a nationwide build-up strategy, with a target of 15 to 30 additional acquisitions per year to double the group's size. Financially, the deal is supported by a unitranche debt facility provided by ICG, which was restructured to accommodate the group's new growth ambitions. This platform investment highlights the ongoing institutionalization of the French medical imaging market, where specialized financial sponsors provide the dry powder necessary for heavy equipment modernization and digital transformation, particularly in AI and tele-radiology.
IMDEV, which reported an EBITDA margin of LOGIN in 2023, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.4x).
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Imdev is a premier French medical imaging network that has rapidly ascended to a leadership position within the highly regulated healthcare infrastructure sector. Founded in 2019 by radiologists, the group operates a comprehensive network of 120 centers (2024), with a particularly dominant footprint in the Île-de-France region. Its business model integrates a wide spectrum of diagnostic services, including classical radiology and nuclear medicine, through a presence in both urban private practices and public-private partnerships within hospitals and clinics. The company employs approximately 1,000 staff members, including 200 liberal radiologists, and leverages an advanced technical platform to deliver high-quality medical acts.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Similar deals in Healthcare & Pharma
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 05/2025 | FONDATION SANTE SERVICE | CLARIANE HAD (HOME HOSPITALIZATION SERVICES) | FRANCE | Health Providers | Clariane sells its French home hospitalization business to the leader of the sector in France, Fondation Sante Service. The deal is part of Clariane's EUR1bn asset disposal plan to strengthen its balance sheet. |
| 04/2025 | EUROFINS SCIENTIFIC | SYNLAB SPAIN | SPAIN | Health Providers | Eurofins Scientific has completed the acquisition of 100% of SYNLAB’s clinical diagnostics operations in Spain. The transaction, initially agreed upon in October 2024, was finalized on March 31, 2025. This strategic carve-out allows SYNLAB to optimize its portfolio by exiting the Spanish market to focus on regions with higher strategic impact. For Eurofins, the acquisition is transformative, merging SYNLAB’s assets with its existing Eurofins Megalab network to become the undisputed leader in clinical diagnostics in Spain. The combined entity now possesses a workforce of over 2,000 employees and the capacity to serve more than 10 million patients annually, processing over 100 million tests. The strategic rationale centers on total geographic coverage of Spain and enhanced capabilities in specialized testing such as genetics. The deal was integrated without significant restructuring due to the complementary nature of the laboratory footprints. |
| 12/2024 | SONIC HEALTHCARE | LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES | GERMANY | Health Providers | Sonic Healthcare has signed binding agreements to acquire the LADR Laboratory Group, marking a substantial expansion of its German and European diagnostic footprint. The transaction was structured on a cash and debt-free basis, with a total consideration satisfied through a mix of Sonic ordinary shares (up to 222 million euros) and cash funded from existing facilities. The strategic rationale centers on the strong cultural and operational alignment between the two organizations, with significant synergy potential identified in procurement, laboratory overlaps, logistics, and equipment maintenance. The deal also includes an inherited put/call structure for a separate German laboratory business, expected to be fully consolidated by 2027. Following the acquisition, the target's senior leadership, including the CEO and Medical Director, will remain with the group to lead the integration collaboratively with the acquirer’s German division. |
| 11/2024 | WELLTOWER | CARE UK | UNITED KINGDOM | Health Providers | Bridgepoint divested its entire stake in Care UK to Welltower, a US healthcare REIT, marking the conclusion of approximately 14 years of private equity ownership. Bridgepoint had originally acquired Care UK in 2010 and had previously attempted an unsuccessful sale process, incurring £2.5 million in abortive advisory costs as disclosed in its 2019 accounts. The deal excludes Practice Plus Group, which was carved out by Bridgepoint in 2019 and remains under its ownership. Bridgepoint was advised by Barclays (corporate finance), Allen & Overy (legal), and EY (financial and tax). |
| 11/2024 | GROUPE IMAGERIE CARDINET | RADIOLOGIE PARIS OUEST | FRANCE | Health Providers | Groupe Imagerie Cardinet acquired 100% of Radiologie Paris Ouest from its previous majority shareholder, Azulis Capital, which had held a stake since 2019. The transaction was financed with the support of Andera Acto (Andera Partners' sponsorless/mezzanine arm), which had already invested in Cardinet in 2023. A critical feature of the deal is the significant reinvestment by RPO's 20 radiologist-associates, who rolled over more than 50% of their proceeds into the combined holding company. This merger creates a major regional champion in the Ile-de-France area, with a combined pool of over 60 partner-physicians and a dense network of centers across Paris and its western and eastern suburbs. |
| 10/2024 | MONTEFIORE INVESTMENT | DEMENEGO | ITALY | Health Providers | Montefiore Investment acquired a majority stake in Demenego from Vam Investments. This secondary LBO follows a highly successful four-year period of ownership by the seller, during which the company more than doubled its revenue and expanded its retail network from 15 to 39 stores. The new partnership is designed to build on this solid foundation, with a strategic focus on further transforming the eyewear specialist into a national leader through innovation and omnichannel development. The investment strategy emphasizes continued significant investment in digitalization, customization technology, and the expansion of the "Demenego Labs" concept. The CEO and management team remain in place to execute this next phase of growth, aiming to capitalize on the firm's reputation for visual healthcare and rapid production capabilities. The transaction highlights the group's position as a high-margin, specialized retail platform in a consolidating European market. |
| 10/2024 | QUALIUM | IMPC (IMAGERIE MEDICALE PARIS CENTRE) | FRANCE | Health Providers | Qualium Investissement is acquiring a 25% minority stake in IMPC from its associate radiologists. This primary LBO transaction follows a strategic period of reflection during which the founding doctors chose to maintain operational and capital control of their group rather than pursuing a majority sale. The operation is designed to provide the necessary capital to fund a targeted external growth strategy, particularly in the Paris region, while offering a medical-led alternative to the broader consolidation of the imaging market. A significant portion of the deal structure involves doubling the number of associates to integrate a new generation of radiologists into the group's governance. The transaction is supported by a senior debt facility that includes a substantial capital expenditure line for future acquisitions aimed at reinforcing the group's medical specialties. This partnership emphasizes long-term independence and professional excellence in a rapidly evolving regulatory and financial environment for medical practices. |
| 10/2024 | ARDIAN | VISTA VISION | ITALY | Health Providers | Ardian Expansion acquired a majority stake in Vista Vision from its founders and Credem Private Equity. The transaction marks a new strategic phase for the group, following a period of rapid expansion where revenues tripled under Credem's tenure. The founders reinvested significantly alongside Ardian to remain minority shareholders and lead the next growth cycle. The strategic roadmap focuses on aggressive buy-and-build activity in the highly fragmented Italian market—with eight acquisitions already in the pipeline—and international expansion across Romania and other European countries. The deal highlights the "social infrastructure" appeal of specialized healthcare services driven by increasing demand for elective surgeries and advanced ophthalmic care. |
| 08/2024 | ORLANDO HEALTH | BROOKWOOD BAPTIST HEALTH SERVICES | UNITED STATES | Health Providers | Orlando Health signed a definitive agreement to acquire Tenet Healthcare's majority interest in Baptist Health, the faith-based integrated health system operating across Central Alabama. Upon closing, Orlando Health will become the majority and managing partner of Baptist Health, assuming day-to-day operational management of the system in partnership with Baptist Health System, which retains its minority stake and continues to anchor the organisation's faith-based mission. At the time of the transaction, the system comprised five hospitals across Central Alabama with more than 1,700 beds, over 70 primary and specialty care clinics, approximately 1,500 affiliated physicians, and more than 7,300 employees. |
| 06/2024 | L-GAM / CAPZA / IDIA CAPITAL INVESTISSEMENT | PSV GROUP | FRANCE | Health Providers | L-GAM, CAPZA, IDIA Capital Investissement, and Bpifrance are acquiring a minority stake in PSV Group from its associate physicians. The transaction allows for the entry of a consortium of minority financial partners while ensuring that the associate doctors, who remain majority shareholders, retain full operational and strategic control of the group. This strategic partnership is designed to provide the financial resources and complementary expertise required to support an ambitious new development phase. Specifically, the investment will fund the construction of a new specialized center in Lens while allowing the group to accelerate its medical project and advance its sustainable development goals. The operation focuses on maintaining the group's long-term independence and ensuring medical excellence in cancer care for the regional population. |
REFERENCES
Revenue range: 100M - 200M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of IMDEV by CAPZA are reserved for mynth community members. Register for free to unlock full data.
Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).
Target: imdev
Acquirer: capza